600 related articles for article (PubMed ID: 24141006)
21. Hematopoietic cell transplantation comorbidity index (HCT-CI) is predictive of adverse events and overall survival in older allogeneic transplant recipients.
Keller JW; Andreadis C; Damon LE; Kaplan LD; Martin TG; Wolf JL; Ai WZ; Venstrom JM; Smith CC; Gaensler KM; Hwang J; Olin RL
J Geriatr Oncol; 2014 Jul; 5(3):238-44. PubMed ID: 24894413
[TBL] [Abstract][Full Text] [Related]
22. Comorbidity index does not predict outcome in allogeneic myeloablative transplants conditioned with fludarabine/i.v. busulfan (FluBu4).
Patel P; Sweiss K; Nimmagadda S; Gao W; Rondelli D
Bone Marrow Transplant; 2011 Oct; 46(10):1326-30. PubMed ID: 21132027
[TBL] [Abstract][Full Text] [Related]
23. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
[TBL] [Abstract][Full Text] [Related]
24. Predictive value of risk assessment scores in patients with hematologic malignancies undergoing reduced-intensity conditioning allogeneic stem cell transplantation.
Yamamoto W; Ogusa E; Matsumoto K; Maruta A; Ishigatsubo Y; Kanamori H
Am J Hematol; 2014 Sep; 89(9):E138-41. PubMed ID: 24845702
[TBL] [Abstract][Full Text] [Related]
25. Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
Baron F; Lechanteur C; Willems E; Bruck F; Baudoux E; Seidel L; Vanbellinghen JF; Hafraoui K; Lejeune M; Gothot A; Fillet G; Beguin Y
Biol Blood Marrow Transplant; 2010 Jun; 16(6):838-47. PubMed ID: 20109568
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation.
Salit RB; Oliver DC; Delaney C; Sorror ML; Milano F
Biol Blood Marrow Transplant; 2017 Apr; 23(4):654-658. PubMed ID: 28189904
[TBL] [Abstract][Full Text] [Related]
27. Busulfan dose intensity and outcomes in reduced-intensity allogeneic peripheral blood stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia.
Chen YB; Coughlin E; Kennedy KF; Alyea EP; Armand P; Attar EC; Ballen KK; Cutler C; Dey BR; Koreth J; McAfee SL; Spitzer TR; Antin JH; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2013 Jun; 19(6):981-7. PubMed ID: 23562738
[TBL] [Abstract][Full Text] [Related]
28. Prognostic role of pre-transplantation serum C-reactive protein levels in patients with acute leukemia undergoing myeloablative allogeneic stem cell transplantation.
Akı ŞZ; Suyanı E; Bildacı Y; Çakar MK; Baysal NA; Sucak GT
Clin Transplant; 2012; 26(5):E513-21. PubMed ID: 23061760
[TBL] [Abstract][Full Text] [Related]
29. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
[TBL] [Abstract][Full Text] [Related]
30. The hematopoietic cell transplantation specific comorbidity index and survival after extracorporeal photopheresis, pentostatin, and reduced dose total body irradiation conditioning prior to allogeneic stem cell transplantation.
Hashmi S; Oliva JL; Liesveld JL; Phillips GL; Milner L; Becker MW
Leuk Res; 2013 Sep; 37(9):1052-6. PubMed ID: 23830733
[TBL] [Abstract][Full Text] [Related]
31. Donor selection for killer immunoglobulin-like receptors B haplotype of the centromeric motifs can improve the outcome after HLA-identical sibling hematopoietic stem cell transplantation.
Zhou H; Bao X; Wu X; Tang X; Wang M; Wu D; He J
Biol Blood Marrow Transplant; 2014 Jan; 20(1):98-105. PubMed ID: 24516895
[TBL] [Abstract][Full Text] [Related]
32. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML.
Lim ZY; Ingram W; Brand R; Ho A; Kenyon M; Devereux S; Marsh J; Mufti GJ; Pagliuca A
Bone Marrow Transplant; 2010 Apr; 45(4):633-9. PubMed ID: 19767782
[TBL] [Abstract][Full Text] [Related]
33. Admission of hematopoietic cell transplantation patients to the intensive care unit at the Pontificia Universidad Católica de Chile Hospital.
Escobar K; Rojas P; Ernst D; Bertin P; Nervi B; Jara V; Garcia MJ; Ocqueteau M; Sarmiento M; Ramirez P
Biol Blood Marrow Transplant; 2015 Jan; 21(1):176-9. PubMed ID: 25139214
[TBL] [Abstract][Full Text] [Related]
34. Single infusion of donor mononuclear early apoptotic cells as prophylaxis for graft-versus-host disease in myeloablative HLA-matched allogeneic bone marrow transplantation: a phase I/IIa clinical trial.
Mevorach D; Zuckerman T; Reiner I; Shimoni A; Samuel S; Nagler A; Rowe JM; Or R
Biol Blood Marrow Transplant; 2014 Jan; 20(1):58-65. PubMed ID: 24140121
[TBL] [Abstract][Full Text] [Related]
35. Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
Finke J; Schmoor C; Bethge WA; Ottinger HD; Stelljes M; Zander AR; Volin L; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Bertz H; Grishina O; Socié G;
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1716-26. PubMed ID: 22713691
[TBL] [Abstract][Full Text] [Related]
36. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: a single Japanese transplant centre study.
Kataoka K; Nannya Y; Ueda K; Kumano K; Takahashi T; Kurokawa M
Bone Marrow Transplant; 2010 Mar; 45(3):513-20. PubMed ID: 19684632
[TBL] [Abstract][Full Text] [Related]
37. Does the hematopoietic cell transplantation specific comorbidity index predict transplant outcomes? A validation study in a large cohort of umbilical cord blood and matched related donor transplants.
Majhail NS; Brunstein CG; McAvoy S; DeFor TE; Al-Hazzouri A; Setubal D; Arora M; Le CT; Wagner JE; Weisdorf DJ
Biol Blood Marrow Transplant; 2008 Sep; 14(9):985-992. PubMed ID: 18721761
[TBL] [Abstract][Full Text] [Related]
38. Relationship of body mass index and arm anthropometry to outcomes after pediatric allogeneic hematopoietic cell transplantation for hematologic malignancies.
Hoffmeister PA; Storer BE; Macris PC; Carpenter PA; Baker KS
Biol Blood Marrow Transplant; 2013 Jul; 19(7):1081-6. PubMed ID: 23623893
[TBL] [Abstract][Full Text] [Related]
39. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation.
Artz AS; Wickrema A; Dinner S; Godley LA; Kocherginsky M; Odenike O; Rich ES; Stock W; Ulaszek J; Larson RA; van Besien K
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1209-16. PubMed ID: 18940674
[TBL] [Abstract][Full Text] [Related]
40. Adjusting DLCO for Hb and its effects on the Hematopoietic Cell Transplantation-specific Comorbidity Index.
Coffey DG; Pollyea DA; Myint H; Smith C; Gutman JA
Bone Marrow Transplant; 2013 Sep; 48(9):1253-6. PubMed ID: 23503530
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
